Jonathan B. Zung - 19 Jul 2022 Form 4 Insider Report for Evelo Biosciences, Inc.

Reporting relationship: Chief Development Officer
Issuer ticker: N/A
Reported as of: 19 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Oct 2022, 16:32:41 UTC
Prior SEC filing: 21 Jan 2022
Next SEC filing: 03 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Daniel S. Char, Attorney-in-Fact for Jonathan B. Zung

Key filing fact

Jonathan B. Zung filed Form 4 for Evelo Biosciences, Inc. on 14 Oct 2022.

Key facts

This page summarizes Jonathan B. Zung's Form 4 filing for Evelo Biosciences, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Oct 2022, 16:32.

Change

Previous filing in this sequence was filed on 21 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EVLO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +115,000
Change %
Price: $0.000000
Shares after: 115,000
Date: 19 Jul 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 115,000
Exercise price: $2.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest as to 50% of the underlying shares on the first anniversary of the date of grant, and as to the remaining 50% of the underlying shares on the second anniversary of the date of grant.